MESO News & Events

Latest data shows the largest indicative borrow rate increases among liquid option names include: Grabagun Digital Holdings Inc. (PEW) 5.85% +3.97, Direxion Daily 20 plus Year Treasury Bear 3X Shares (TMV) 33.13% +1.91, Mesoblast (MESO) 16.87% +1.06, T-REX 2X Long BMNR Daily Target ETF (BMNU) 24.42% +0.73, Olaplex Holdings (OLPX) 1.97% +0.64, iShares Turkey (TUR) 9.26% +0.53, Gold Bear 3x (DUST) 10.85% +0.42, Tenneco Inc (TEN) 1.75% +0.32, TSLR ETF (TSLR) 6.39% +0.30, and Novartis (NVS) 0.59% +0.26.

Latest data shows the largest indicative borrow rate increases among liquid option names include: Kodiak AI, Inc. Common Stock (KDK) 42.04% +5.03, Novartis (NVS) 12.19% +3.96, ProShares UltraShort Silver (ZSL) 42.00% +2.63, Klarna Group PLC (KLAR) 101.46% +2.01, Medical Properties Trust, Inc (MPT) 3.35% +1.36, Mesoblast (MESO) 11.02% +1.06, Veeva (VEEV) 0.98% +0.69, T-REX 2X INVERSE MSTR DAILY TARGET (MSTZ) 38.34% +0.62, Nano Nuclear Energy Inc (NNE) 12.59% +0.60, and Microvision (MVIS) 8.32% +0.56.

Latest data shows the largest indicative borrow rate increases among liquid option names include: DIREXION DAILY GOOGL BULL 1.5X SHARES ETF (GGLL) 5.46% +0.71, T-REX 2X LONG MSTR DAILY TARGET (MSTU) 35.34% +0.65, ProShares Short VIX Short Term Futures (SVXY) 2.26% +0.62, ChargePoint Holdings (CHPT) 15.47% +0.54, Direxion Daily Smal Cap Bull 3X Shares (TNA) 3.76% +0.43, T-REX 2X Long BMNR Daily Target ETF (BMNU) 29.72% +0.27, FuelCell (FCEL) 3.18% +0.26, GDS Holdings (ADS) (GDS) 1.50% +0.21, Mesoblast (MESO) 4.52% +0.21, and 3M (MMM) 0.42% +0.17.

Mesoblast provided feedback received from the U.S. Food & Drug Administration, FDA, on potential filing of a Biologics License Application, BLA, for its allogeneic cell therapy product rexlemestrocel-L in patients with chronic discogenic low back pain, CLBP. This follows FDA's Type B meeting review of data from Mesoblast's first randomized controlled Phase 3 trial, MSB-DR003, on pain reduction and relationship to decreased use or elimination of opioids for up to three years following a single rexlemestrocel-L administration. Mesoblast is seeking FDA approval for rexlemestrocel-L based on reduction in CLBP through 12 months. Comparing outcomes between rexlemestrocel-L and placebo from MSB-DR003 trial, FDA acknowledged that the effects on pain intensity appear to favor the active arm. FDA also confirmed that a clinically meaningful reduction in pain intensity in the active arm versus placebo at 12 months can support product efficacy and stated that the robust results on opioid reduction from at least one adequate and well controlled trial could be included in the Clinical Studies section of product labeling.